20 July 2018 - PHARMAC is seeking feedback on a proposal to fund a pangenotypic treatment for chronic hepatitis C infection, glecaprevir and pibrentasvir (Maviret), through a provisional agreement with AbbVie Ltd. And we also seek feedback on the proposed distribution arrangements.

In summary, this proposal would result in the following changes at a date to be determined:

• Glecaprevir and pibrentasvir (Maviret) 100 mg/40 mg tablets would be funded in the community and DHB hospitals without restrictions for patients with chronic hepatitis C.
  
• Listing would be no earlier than 1 October 2018. The list date would be confirmed as soon as possible pending Medsafe approval of a Changed Medicine Notification for Maviret.
  
• Maviret would replace Viekira Pak and Viekira Pak-RBV.
  

Read PHARMAC consultation